Procter & Gamble Health Limited has reported its unaudited financial results for the quarter ended September 30, 2024, showing steady revenue growth and a notable increase in profitability.
For Q2 FY2025, the company recorded a revenue from operations of ₹313.41 crore, representing a 2.8% rise from ₹304.93 crore in the same quarter last year. This growth highlights the company’s resilience amid competitive market conditions.
The net profit for the quarter saw a significant jump, reaching ₹82.33 crore, a 25.6% increase compared to ₹65.57 crore in Q2 FY2024. This robust profit growth underscores the company’s effective cost management and operational efficiencies.
The company remains focused on delivering value to shareholders and expanding its market presence, maintaining its strong financial position in the industry.
